| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
marketing1@energy-chemical.com |
| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | BICAPPA Basic information |
| Product Name: | BICAPPA | | Synonyms: | 6-chloro-N-[3-[4-[3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl]piperazin-1-yl]propyl]-2-methoxyacridin-9-amine;1,4-Piperazinedipropanamine, N1,N4-bis(6-chloro-2-methoxy-9-acridinyl)-;BiCAPPA >=97% (HPLC), solid | | CAS: | 119662-55-4 | | MF: | C38H40Cl2N6O2 | | MW: | 683.67 | | EINECS: | | | Product Categories: | | | Mol File: | 119662-55-4.mol |  |
| | BICAPPA Chemical Properties |
| storage temp. | 2-8°C | | solubility | DMSO: ~10 mg/mL | | form | solid | | color | yellow |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 |
| | BICAPPA Usage And Synthesis |
| Uses | BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrPSc) from scrapie-infected cells, with an EC50 of 0.32 μM[1][2]. | | References | [1] Uliassi E, et, al. 10-Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. Design of Hybrid Molecules for Drug Development. 2017, Pages 259-277.
[2] Bongarzone S, et, al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem. 2010 Nov 25;53(22):8197-201. DOI:10.1021/jm100882t |
| | BICAPPA Preparation Products And Raw materials |
|